Zentalis Pharmaceuticals Statistics
Share Statistics
Zentalis Pharmaceuticals has 71.27M shares outstanding. The number of shares has increased by 0.43% in one year.
| Shares Outstanding | 71.27M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.22% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 57.60M |
| Failed to Deliver (FTD) Shares | 57.30K |
| FTD / Avg. Volume | 4.52% |
Short Selling Information
The latest short interest is 5.50M, so 7.72% of the outstanding shares have been sold short.
| Short Interest | 5.50M |
| Short % of Shares Out | 7.72% |
| Short % of Float | 9.55% |
| Short Ratio (days to cover) | 5.16 |
Valuation Ratios
The PE ratio is -3.39 and the forward PE ratio is -1.22.
| PE Ratio | -3.39 |
| Forward PE | -1.22 |
| PS Ratio | 0 |
| Forward PS | 11.3 |
| PB Ratio | 2.27 |
| P/FCF Ratio | -4.75 |
| PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Zentalis Pharmaceuticals Inc..
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.16, with a Debt / Equity ratio of 0.
| Current Ratio | 7.16 |
| Quick Ratio | 7.16 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -0.67% and return on capital (ROIC) is -51.7%.
| Return on Equity (ROE) | -0.67% |
| Return on Assets (ROA) | -0.53% |
| Return on Capital (ROIC) | -51.7% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -2.36M |
| Employee Count | 124 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | -601.00K |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -78.88% in the last 52 weeks. The beta is 1.74, so Zentalis Pharmaceuticals 's price volatility has been higher than the market average.
| Beta | 1.74 |
| 52-Week Price Change | -78.88% |
| 50-Day Moving Average | 3.32 |
| 200-Day Moving Average | 6.26 |
| Relative Strength Index (RSI) | 50.96 |
| Average Volume (20 Days) | 1.27M |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.39M |
| Operating Income | -248.99M |
| Net Income | -292.19M |
| EBITDA | -275.50M |
| EBIT | n/a |
| Earnings Per Share (EPS) | -4.47 |
Balance Sheet
The company has 28.04M in cash and 43.15M in debt, giving a net cash position of -15.11M.
| Cash & Cash Equivalents | 28.04M |
| Total Debt | 43.15M |
| Net Cash | -15.11M |
| Retained Earnings | -888.56M |
| Total Assets | 450.66M |
| Working Capital | 345.39M |
Cash Flow
In the last 12 months, operating cash flow was -207.82M and capital expenditures -583.00K, giving a free cash flow of -208.41M.
| Operating Cash Flow | -207.82M |
| Capital Expenditures | -583.00K |
| Free Cash Flow | -208.41M |
| FCF Per Share | -3.19 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZNTL does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -137.54% |
| FCF Yield | -90.12% |
Analyst Forecast
The average price target for ZNTL is $8.5, which is 161.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $8.5 |
| Price Target Difference | 161.5% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Scores
| Altman Z-Score | -2.22 |
| Piotroski F-Score | 3 |